JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 49:442-449, doi:10.1016/j.jacc.2006.09.034 (Published online 11 January 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.09.034v1
49/4/442    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lehrke, M.
Right arrow Articles by Reilly, M. P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lehrke, M.
Right arrow Articles by Reilly, M. P.

CLINICAL RESEARCH: CORONARY ARTERY DISEASE

CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans

Michael Lehrke, MD*,§, Segan C. Millington, BS*, Martina Lefterova, BS*, Reshmaal Gomes Cumaranatunge, MD{dagger}, Philippe Szapary, MD, MSCE{dagger},{ddagger},5, Robert Wilensky, MD, FACC{dagger},4, Daniel J. Rader, MD*,{dagger},{ddagger},2, Mitchell A. Lazar, MD, PhD*,3 and Muredach P. Reilly, MB, MSCE*,{dagger},{ddagger},1,*

* Institute of Diabetes, Obesity, and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
{dagger} Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
{ddagger} Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
§ Department of Gastroenterology, Endocrinology, and Metabolism, Ludwig-Maximilians University of Munich, Munich, Germany.

Manuscript received July 10, 2006; revised manuscript received August 24, 2006, accepted September 11, 2006.

* Reprint requests and correspondence: Dr. Muredach P. Reilly, Cardiovascular Division, University of Pennsylvania Medical Center, 909 BRB 2/3, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104-6160. (Email: muredach{at}spirit.gcrc.upenn.edu).

OBJECTIVES: This study was designed to determine the association of CXCL16 with inflammation, atherosclerosis, and acute coronary syndromes.

BACKGROUND: Vascular inflammation coincides with uptake of modified lipoproteins in the pathogenesis of atherosclerosis. CXCL16 is a protein that shares scavenger receptor function, promoting uptake of modified lipids, with the activities of an inflammatory chemokine. However, the role of CXCL16 in atherosclerosis remains uncertain.

METHODS: The effect of inflammatory stimuli on CXCL16 gene and protein expression was studied in macrophages, mice, and humans, and the association of sol-CXCL16 with risk factors, atherosclerosis, and acute coronary syndromes was determined in humans.

RESULTS: Endotoxin induction of CXCL16 in human macrophages was attenuated by aspirin, nuclear factor (NF)-kappa-B inhibition and peroxisome proliferator-activated receptor (PPAR)-gamma agonists. Experimental human endotoxemia (n = 6) led to an 8-fold increase in whole-blood CXCL16 messenger ribonucleic acid (p < 0.001) and a 1.7-fold increase in soluble (sol)-CXCL16 (p < 0.001), a cleaved active chemokine. Rosiglitazone-blocked endotoxin induced sol-CXCL16 in mice (p = 0.001), and pioglitazone (n = 28), compared to placebo (n = 28), lowered plasma sol-CXCL16 in metabolic syndrome subjects (p < 0.05). In a nested case-control study of acute and chronic coronary artery disease (n = 699), sol-CXCL16 levels correlated with inflammatory and metabolic risk factors and were associated with chronic coronary artery disease (odds ratio [OR] [95% confidence interval], above vs. below median; 1.60 [1.01 to 2.58]; p = 0.04) and acute coronary syndromes (OR 2.52 [1.32 to 4.82], p = 0.005) following adjustment for established risk factors, medications, and C-reactive protein levels.

CONCLUSIONS: Our findings suggest that CXCL16 may play a pro-inflammatory role in human atherosclerosis, particularly in acute coronary syndrome.

Abbreviations and Acronyms
  ACS = acute coronary syndromes
  CAD = coronary artery disease
  CRP = C-reactive protein
  CVD = cardiovascular disease
  ELISA = enzyme-linked immunosorbent assay
  HDL = high-density lipoprotein
  IFN = interferon
  LPS = lipopolysaccharide
  ox-LDL = oxidized low-density lipoprotein
  RNA = ribonucleic acid
  TG = triglycerides
  TNF = tumor necrosis factor




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
C. Smith, B. Halvorsen, K. Otterdal, T. Waehre, A. Yndestad, B. Fevang, W. J. Sandberg, U. M. Breland, S. S. Froland, E. Oie, et al.
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins
Cardiovasc Res, July 1, 2008; 79(1): 195 - 203.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.